BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25277184)

  • 1. TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.
    Caratozzolo MF; Valletti A; Gigante M; Aiello I; Mastropasqua F; Marzano F; Ditonno P; Carrieri G; Simonnet H; D'Erchia AM; Ranieri E; Pesole G; Sbisà E; Tullo A
    Oncotarget; 2014 Sep; 5(17):7446-57. PubMed ID: 25277184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
    Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
    Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIM8 modulates p53 activity to dictate cell cycle arrest.
    Caratozzolo MF; Micale L; Turturo MG; Cornacchia S; Fusco C; Marzano F; Augello B; D'Erchia AM; Guerrini L; Pesole G; Sbisà E; Merla G; Tullo A
    Cell Cycle; 2012 Feb; 11(3):511-23. PubMed ID: 22262183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.
    Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
    Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.
    Roberts AM; Watson IR; Evans AJ; Foster DA; Irwin MS; Ohh M
    Cancer Res; 2009 Dec; 69(23):9056-64. PubMed ID: 19920202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
    Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
    Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.
    Huang J; Kong W; Zhang J; Chen Y; Xue W; Liu D; Huang Y
    Int J Oncol; 2016 Oct; 49(4):1569-75. PubMed ID: 27431728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
    Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
    J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
    Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
    Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
    Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
    Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of miR-34a-5p can rescue disruption of the p53-DAPK axis to suppress progression of clear cell renal cell carcinoma.
    Jing ZF; Bi JB; Li Z; Liu X; Li J; Zhu Y; Zhang XT; Zhang Z; Li Z; Kong CZ
    Mol Oncol; 2019 Oct; 13(10):2079-2097. PubMed ID: 31294899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
    Li CY; Yao AM; Chang XN; Guo YH; Xu R
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
    Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
    BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM8 Blunts the Pro-proliferative Action of ΔNp63α in a p53 Wild-Type Background.
    Caratozzolo MF; Marzano F; Abbrescia DI; Mastropasqua F; Petruzzella V; Calabrò V; Pesole G; Sbisà E; Guerrini L; Tullo A
    Front Oncol; 2019; 9():1154. PubMed ID: 31781486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
    Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
    FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21‑cyclin E2‑Bax/caspase-3 signaling pathway.
    Liu Z; Lu Y; Xiao Y; Lu Y
    Oncol Rep; 2017 Mar; 37(3):1437-1444. PubMed ID: 28184919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
    Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
    Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.